Document is current

Any future updates will be listed below

NSCLC: Immunmonotherapie bei PD-L1-Hochexprimierern besonders effektiv?

Crossref DOI link: https://doi.org/10.1007/s15015-022-3835-x

Published Online: 2022-04-05

Published Print: 2022-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark